The global Sintilimab market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). Sintilimab is a fully human IgG4 monoclonal antibody medication that binds to programmed cell death protein 1 for the treatment of Hodgkin’s disease. The major factor attributing to the growth of the global sintilimab market is the rising […]